A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes

The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.

Start Date28 Aug 2025

Sponsor / Collaborator

Novo Nordisk A/S

NCT07112339

/ RecruitingPhase 4

EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice

This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.

Start Date15 Aug 2025

Sponsor / Collaborator

Novo Nordisk A/S

NCT07076199

/ RecruitingPhase 3

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.

Start Date11 Aug 2025

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Icodec Insulin

100 Translational Medicine associated with Icodec Insulin

100 Patents (Medical) associated with Icodec Insulin

115

Literatures (Medical) associated with Icodec Insulin

01 Jan 2026·DIABETES OBESITY & METABOLISM

Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis

Review

Author: Perrini, Sebastio ; Caporusso, Mariangela ; Natalicchio, Annalisa ; Cignarelli, Angelo ; Laviola, Luigi ; Giorgino, Francesco ; Sorice, Gian Pio ; Di Molfetta, Sergio ; Di Gioia, Ludovico ; Caruso, Irene

Abstract:

Aims:

Once‐weekly basal insulins may offer similar or superior HbA1c reduction compared to once‐daily analogues in people with type 1 or type 2 diabetes. However, concerns about hypoglycaemia persist in individuals on multiple daily injections. This meta‐analysis (PROSPERO CRD42024606874) aimed to evaluate the efficacy and safety of once‐weekly basal insulin therapy in type 1 diabetes.

Materials and Methods:

A systematic search was conducted in MEDLINE, Web of Science and CENTRAL up to 1 April 2025. We included randomized controlled trials (RCTs) comparing insulin icodec or efsitora against once‐daily basal insulins in people with type 1 diabetes. Three reviewers independently evaluated the retrieved citations. The primary outcome was the change in HbA1c. Meta‐analysis was performed using fixed‐ or random‐effects models based on heterogeneity.

Results:

Five RCTs were included, enrolling 1629 adults living with type 1 diabetes. Once‐weekly and once‐daily basal insulins had similar effects on HbA1c (high certainty), body weight (moderate certainty), time in range (moderate certainty) and time above range. However, safety concerns emerged due to increased rates of level 3 hypoglycaemia (incidence rate ratio 2.532, 95% confidence interval [CI] 1.758–3.645; moderate certainty). A significantly lower weekly bolus insulin dose was observed with once‐weekly basal insulin therapy (estimated treatment ratio 0.837, 95% CI 0.794–0.882, I2 = 0%; high certainty).

Conclusions:

This meta‐analysis is the first to evaluate the efficacy and safety of once‐weekly basal insulin therapy exclusively in adults with type 1 diabetes and including all published RCTs. The analysis demonstrated a similar glucose‐lowering effect compared to once‐daily basal insulin but revealed an increased occurrence of severe hypoglycaemia.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada

Article

Author: Mau, Godfrey ; Garcia, David A. ; Singh, Sumeet ; Spence, Michaela ; Goldenberg, Ronald ; Jensen, Morten Sall

AIM:

Patients with type 2 diabetes (T2D) with poor glycemic control despite use of non-insulin agents can experience delay in initiating insulin therapy and poor adherence to insulin therapy, predominantly due to the burden of multiple injections^1-3. This study aimed to determine the cost-effectiveness of insulin icodec, first once-weekly basal insulin, compared with long-acting basal insulins for improving glycemic control in adults with T2D in Canada.

MATERIALS AND METHODS:

The Swedish Institute of Health Economics T2D Cohort Model was used to analyse three T2D groups: insulin naïve (IN), basal insulin experienced (BIE), and basal-bolus insulin experienced (BBIE). Comparators included insulin glargine, insulin detemir, and insulin degludec. Comparative efficacy was informed by the phase 3 ONWARDS trials of insulin icodec and network meta-analyses (NMA). Time horizon was 40 years. Analyses considered disutilities resulting from vascular complications, age, gender, diabetes duration, hypoglycemia, and injection burden. A 1.5% annual discount rate was used for costs and effects. The average cost per unit for each treatment, accounting for the market share of available formats and biosimilars was calculated. Outcomes were expressed as quality-adjusted life-years (QALYs) and cost-effectiveness as incremental cost utility ratios (ICUR [cost/QALY]).

RESULTS:

In all analyses, insulin icodec dominated insulin degludec and insulin detemir. Compared to insulin glargine U100 and U300, insulin icodec was associated with ICURs of $17,876, $20,844, and $73,253; and $6,439, $8,623, and $45,433 in the IN, BIE, and BBIE populations, respectively.

LIMITATIONS:

Limitations of this economic evaluation include the lack of data for some treatments in certain NMAs, uncertainty regarding the use of the NMA results for a 40-year time horizon, heterogeneous sources of disutilities, and uncertainty regarding the HRQoL benefits of reduced injection frequency.

CONCLUSIONS:

Insulin icodec is a cost-effective treatment option for adult patients with T2D versus once daily basal insulin-analogues publicly reimbursed in Canada.

01 Dec 2025·Diabetes Technology & Therapeutics

Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6

Article

Author: Engberg, Susanne ; Kjaersgaard, Maiken Ina Siegismund ; Mathieu, Chantal ; Kehlet Watt, Sara ; Klonoff, David C. ; Irace, Concetta ; Danne, Thomas ; Russell-Jones, David

Background::

Post hoc evaluation of ONWARDS 6 assessed continuous glucose monitoring (CGM) metrics and CGM-based hypoglycemia with once-weekly insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes.

Methods::

Open CGM data were collected throughout ONWARDS 6. During weeks 0–4, 22–26, and 48–52, time in range (TIR; 3.9–10.0 mmol/L), time above range (TAR; >10.0 mmol/L), and time below range (TBR; <3.9 and <3.0 mmol/L) were assessed by treatment day after icodec injection or degludec titration. Rates of CGM-based clinically significant hypoglycemic episodes (<3.0 mmol/L for ≥15 consecutive min) and durations of CGM-based hypoglycemic episodes (<3.9 mmol/L) and CGM-based periods <3.0 mmol/L were reported (baseline to weeks 26 and 57).

Results::

Although rates of overall CGM-based clinically significant hypoglycemia were statistically significantly higher with icodec than degludec from baseline to week 26 and week 57, estimated rate ratios (icodec/degludec) for CGM-based clinically significant hypoglycemic episodes were lower than those estimated from self-measured blood glucose (SMBG) data from baseline to week 26 (1.38 vs. 1.88) and to week 57 (1.28 vs. 1.79). Observed percentage of TIR was highest on days 2–4 after icodec injection with a concomitant reduction in TAR and an increase in TBR. Median duration of CGM-based hypoglycemic episodes was comparable between treatment arms from baseline to week 26 (icodec: 35 min; degludec: 30 min) and to week 57 (35 min for both treatments). Median duration of CGM-based periods <3.0 mmol/L was the same for both treatments at week 26 and week 57 (25 min).

Conclusion::

In adults with type 1 diabetes, estimated rate ratios for CGM-based clinically significant hypoglycemia were lower than those estimated from SMBG data, although still favoring degludec with estimated rate ratios of 1.28–1.38. CGM metrics varied by treatment day after icodec injection, but median duration of CGM-based hypoglycemia was comparable between treatment arms.

News (Medical) associated with Icodec Insulin

16 Jan 2026

·endpoints.news

European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations last year, 38 were for new active substances — novel molecules, as opposed to reformulations or generics, for instance — according to the report. That figure markedly lags the 53 new treatments greenlit by the FDA in 2025. The total number was second only to the 114 drugs recommended in 2024. “If you look back over the past 15 years, you will see the number waxes and wanes, but there was a big dip during Covid-19,” EMA chief medical officer Steffen Thirstrup said in a press briefing on Thursday. “Some of what we saw [in 2024] was…a wave of things that had been postponed and protracted during Covid-19, and 104 is still a very high number of approvals from a European perspective.” Several new products were approved in the US last year but are still awaiting European authorization. These include Milestone Pharmaceuticals’ Cardamyst, approved in the US in December for an arrhythmia disorder called paroxysmal supraventricular tachycardia. Milestone has submitted an application in the EU for the drug under the name Tachymist, but a decision is not expected until the first quarter of 2027, showing just how long the delay between the two regulators can be. At least one product was approved in Europe but not in the US, however. The European agency recommended Novo Nordisk’s fixed-dose combination of insulin icodec and semaglutide for type 2 diabetes in September, and it was approved in Europe as Kyinsu in November. US approval of Kyinsu is not imminent. The FDA rejected insulin icodec due to manufacturing concerns in 2024. Novo has since resubmitted insulin icodec in the US, but will have to wait for that decision before filing the fixed-dose combination. As a combination of approved drugs, Kyinsu would not count as a novel medicine, however. Endocrinology was the most popular therapeutic area for medicine approvals in Europe last year. The EMA recommended 29 products for endocrine disorders, including three new treatments. These were Bayer’s Lynkuet for menopause symptoms, Sanofi’s Teizeild for type 1 diabetes and Amgen’s Tepezza for thyroid eye disease. Looking to the year ahead, the EMA said it expects continued innovation in weight management and diabetes. The agency has received the first application for a generic version of Novo Nordisk’s older GLP-1 agonist product liraglutide for both indications. Meanwhile, its safety committee is also looking into possible interactions between the drug class and contraceptive pills.

Drug Approval

29 Sep 2025

·www.prnewswire.com

Novo Nordisk resubmits Awiqli® to the FDA with potential to be the first once-weekly basal insulin treatment for adults with type 2 diabetes

Awiqli® (insulin icodec) injection, if approved, has the potential to be the first once-weekly basal insulin treatment available in the US for adult type 2 diabetes In adults with type 2 diabetes, the ONWARDS clinical trial program evaluated the change in A1C from baseline with Awiqli® compared to daily basal insulin1-5 Resubmission reflects Novo Nordisk's 100-year legacy of advancing diabetes care BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes. "With this resubmission, we're closer to offering a new insulin treatment option for people living with type 2 diabetes that, if approved, could reduce their yearly basal insulin injections from 365 to 52," said Anna Windle, PhD, Senior Vice President, Clinical Development, Medical and Regulatory Affairs at Novo Nordisk. "It is critical that we continue to build upon our 100-year legacy in diabetes and long-standing mission to advance science and the ONWARDS clinical program supports our hope that Awiqli® can help streamline the basal insulin injection regimen for people living with type 2 diabetes." The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 About Awiqli® In the US, Awiqli® is an investigational, novel once-weekly basal insulin analog designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. This resubmission is in response to the FDA's action letter received in Q3 2024. Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information References Rosenstock J, Bain C. S, Gowda A, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. The New England Journal of Medicine. 2023 10.1056/NEJMoa2303208 Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023 (23)00093-1 Lingvay I, Asong M, Desouza C, et al. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes The ONWARDS 3 Randomized Clinical Trial. JAMA. 2023 Mathieu C, Ásbjörnsdóttir B, Bajaj H, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. 2023 (23)00520-2 Bajaj H, Aberle J, Davies M, et al. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naïve Type 2 Diabetes (ONWARDS 5). Annals of Internal Medicine. 2023 10.7326/M23-1288 Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25AWQ00001. September 2025 SOURCE Novo Nordisk WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalPhase 2

19 Sep 2025

·www.fiercepharma.com

Novo's once-weekly combo drug for Type 2 diabetes scores EU endorsement

Europe's Committee for Medicinal Products for Human Use has recommended several products for approval, including Novo Nordisk's diabetes drug Kyinsu and Bayer's menopause treatment Lynkuet. A year after Novo Nordisk surrendered its pursuit of an approval in the U.S. for IcoSema as a treatment for Type 2 diabetes, the Danish company has scored a recommendation for the combination drug in Europe.The Committee for Medicinal Products for Human Use (CHMP) has given a thumbs-up to once-weekly Kyinsu, as it is known in Europe, to treat patients with Type 2 diabetes who can’t get sufficient control of their blood sugar with basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists.Kyinsu combines once-weekly insulin Awiqli (icodec) with GLP-1 Type 2 diabetes treatment Ozempic (semaglutide).In July of last year, the FDA rejected icodec as a treatment for Type 1 and Type 2 diabetes, citing its “manufacturing process.” The U.S. regulator also was swayed by a panel of experts who voted 7-4 against recommending it for approval in its Type 1 diabetes indication because of concerns about its potential to trigger episodes of low blood sugar.The FDA’s complete response letter came three months after the European Medicines Agency (EMA) granted marketing authorization to Awiqli as a treatment for Type 1 and Type 2 diabetes, following a positive opinion from CHMP.Drug endorsements for Bayer, Merck and more The CHMP also recommended Bayer’s Lynkuet (elinzanetant) for approval to treat moderate-to-severe hot flashes or night sweats that accompany menopause.In July, the UK and Canada approved the dual-action neurokinin, which targets the NK-3 and NK-1 receptors. The FDA also was expected to sign off on Lynkuet in July, but the regulator pushed the decision date forward by three months to Oct. 26.With nods in the U.S. and Europe, Bayer would join Astellas as the second company with a hormone-free treatment for patients with moderate to severe hot flashes. Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved in the indication and has drawn a peak sales potential projection of $3.6 billion from the company.The CHMP also issued a positive opinion on Merck’s monoclonal antibody Enflonsia to prevent lower respiratory tract disease associated with respiratory syncytial virus (RSV). The shot, which is for infants, was approved by the FDA in June and enters the market as a challenger to AstraZeneca and GSK’s blockbuster Beyfortus.Also making the grade with the CHMP experts was Johnson & Johnson’s Imaavy as a treatment for generalized myasthenia gravis (gMG). The European recommendation comes five months after the FDA endorsed Imaavy in the same indication.After a re-examination, the CHMP has recommended granting marketing authorization for Cosmo Pharmaceuticals’ topical acne treatment Winlevi. The nod comes five months after the committee gave it a thumbs-down. Label expansions The CHMP has endorsed Amgen’s Uplizna as a treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition that can present in multiple organs and cause fibrosis and permanent organ damage, with or without symptoms. The FDA signed off on Uplizna for the disorder in April, five years after the drug hit the market as a treatment for neuromyelitis optica spectrum disorder (NMOSD).Collecting two positive opinions from the CHMP was Merck’s cancer powerhouse Keytruda. One of the nods is to recommend approval of a subcutaneous route of administration for Keytruda and its associated formulation tweak. The recommendation applies to all approved adult indications in Europe. The FDA is expected to decide on the SC version of Keytruda next week.The other thumbs-up is for Keytruda as a treatment for locally advanced head and neck squamous cell carcinoma and comes three months after the FDA signed off on the PD-1 inhibitor in the indication.The CHMP has given a nod to Regeneron and Sanofi’s Dupixent as a treatment for the hives condition, chronic spontaneous urticaria (CSU). The FDA approved Dupixent in the indication in April of this year, making it the first new medicine for CSU in more than a decade.Hipra Human Health has secured a CHMP recommendation for Bimervax as a booster to prevent COVID-19 in those 12 and older who have previously received an mRNA COVID-19 shot. The EU originally approved the booster in 2023 for those aged 16 and older.Also making the grade with CHMP were AstraZeneca and Amgen's Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. AZ's Koselugo got a thumbs-up for symptomatic, inoperable plexiform neurofibromas in adult and pediatric patients with neurofibromatosis type 1 aged 3 years and older.

Drug Approval

100 Deals associated with Icodec Insulin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	European Union	Novo Nordisk A/S	17 May 2024
Diabetes Mellitus	Iceland	Novo Nordisk A/S	17 May 2024
Diabetes Mellitus	Liechtenstein	Novo Nordisk A/S	17 May 2024
Diabetes Mellitus	Norway	Novo Nordisk A/S	17 May 2024
Diabetes Mellitus, Type 1	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024
Diabetes Mellitus, Type 2	Canada	Novo Nordisk Canada, Inc.	12 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05435677 (Pubmed \| Diabetes Ther)	Phase 1	Diabetes Mellitus, Type 2	20	IcoSema	vhntzhimpb(anwweovoea): ratio = 1.04 (90.0% CI, 0.99 - 1.08) View more	Positive	06 Oct 2025
				icodec
NCT04760626 (ONWARDS 1-6 \| ONWARDS 5, CTgov)	Phase 3	Diabetes Mellitus, Type 2	1,085	Insulin icodec (Insulin Icodec)	qtjpcljbya(coqldugxts) = kxudhwqtmf qzsxlvmwab (vqttkpyqdv, 0.09) View more	-	26 Aug 2025
				Insulin (Once Daily Basal Insulin Analogue)	qtjpcljbya(coqldugxts) = hmgcnoakbr qzsxlvmwab (vqttkpyqdv, 0.12) View more
NCT04880850 (ONWARDS 1-6 \| ONWARDS 4, CTgov)	Phase 3	Diabetes Mellitus, Type 2	582	insulin+Insulin icodec+insulin aspart (Insulin Icodec)	lchuishzai(nuroosstge) = bhnqskhrnu ramungokkl (vdfarjwsmh, 0.05) View more	-	02 Jul 2025
				Insulin Glargine (Insulin Glargine)	lchuishzai(nuroosstge) = eclqvqcaub ramungokkl (vdfarjwsmh, 0.05) View more
NCT04460885 (ONWARDS 1-6 \| ONWARDS 1, CTgov)	Phase 3	Diabetes Mellitus, Type 2	984	Insulin icodec (Insulin Icodec)	btummarbhq(gqytxbojlg) = ooybrvshdd tfpxhrkiuv (zdzxhgzfxx, 0.06) View more	-	12 Jun 2025
				Insulin glargine (Insulin Glargine)	btummarbhq(gqytxbojlg) = qjjaegnmpd tfpxhrkiuv (zdzxhgzfxx, 0.05) View more
NCT04848480 (ONWARDS 6 \| ONWARDS 1-6, CTgov)	Phase 3	Diabetes Mellitus, Type 1	582	insulin icodec+insulin aspart (Insulin Icodec + Insulin Aspart)	ntagikyuai(opjpnhbiqv) = ahyjhssyec zuuujqwbwo (xsrpsxjkbi, 0.07) View more	-	12 Jun 2025
				insulin degludec+insulin aspart (Insulin Degludec + Insulin Aspart)	ntagikyuai(opjpnhbiqv) = bexhwaodxr zuuujqwbwo (xsrpsxjkbi, 0.06) View more
NCT04880850 \| NCT04770532 \| NCT04460885 \| NCT04848480 \| NCT04795531 \| NCT04760626 (ONWARDS 1-6, Pubmed \| Diabetes Ther)	Phase 3	-	-	Icodec	oogexffmjl(wkvqsiwjzb) = Mean HbA1c levels remained relatively stable over assessed time points for both treatment groups fjkeujgwki (stchwuazcm ) View more	Positive	04 Jun 2025
				Once-daily comparators (insulin degludec, insulin glargine U100, insulin glargine U300)
NCT05823948 (ONWARDS 9, Pubmed \| Diabetes Technol Ther \| NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	51	Once-weekly Insulin Icodec	krvzwmymjz(ysiswmixmy) = mkhktapdmw umalwywoor (ollpqoiqbs, -1.36 to -0.99)	Positive	05 Mar 2025
NCT04795531 (ONWARDS 3, Pubmed \| Diabetes Ther)	Phase 3	Diabetes Mellitus, Type 2	-	Once-Weekly Insulin Icodec	dvcgzhmidg(lvfqarpoeg): P-Value = 0.0152	Positive	28 Feb 2025
				Once-Daily Insulin Degludec
NCT04770532 (ONWARDS 1-6 \| ONWARDS 2, CTgov)	Phase 3	Diabetes Mellitus, Type 2	526	Insulin Icodec (Insulin Icodec)	ldyggkhhbs(xaivyhyrmt) = fetogldzca qcwlwbzunf (rywcykwvgw, 0.05) View more	-	20 Feb 2025
				Insulin Degludec (Insulin Degludec)	ldyggkhhbs(xaivyhyrmt) = llqnrfydyt qcwlwbzunf (rywcykwvgw, 0.06) View more
NCT04795531 (ONWARDS 1-6 \| ONWARDS 3, CTgov)	Phase 3	Diabetes Mellitus, Type 2	588	placebo+insulin icodec (Insulin Icodec)	rhskerudya(gfcmrsbznl) = bxsjdgzpvx dypjwnzmki (mpnckgyooc, 0.05) View more	-	04 Dec 2024
				Insulin Degludec (Insulin Degludec)	rhskerudya(gfcmrsbznl) = sqzacwpoqa dypjwnzmki (mpnckgyooc, 0.05) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis